Canaccord Genuity initiated coverage on Amyris with a new price target
$AMRS
Major Chemicals
Industrials
Canaccord Genuity initiated coverage of Amyris with a rating of Buy and set a new price target of $1.50
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/18/2023 | $3.10 → $0.65 | Buy → Hold | Jefferies |
| 5/10/2023 | $4.00 → $1.25 | Outperform → Market Perform | TD Cowen |
| 4/28/2023 | $1.50 | Buy | Canaccord Genuity |
| 11/10/2022 | Overweight → Neutral | JP Morgan | |
| 11/9/2022 | Outperform → Perform | Oppenheimer | |
| 8/10/2022 | $4.00 → $2.00 | Buy → Neutral | ROTH Capital |
| 6/24/2022 | Neutral | JP Morgan | |
| 5/25/2022 | $2.50 | Neutral | Piper Sandler |
S-8 POS - AMYRIS, INC. (0001365916) (Filer)
S-8 POS - AMYRIS, INC. (0001365916) (Filer)
S-8 POS - AMYRIS, INC. (0001365916) (Filer)
VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse
Voluntary Chapter 11 Commenced to Finalize Consensual Go-Forward Plan for Amyris' Core Business $190 Million Financing Commitment from Foris Ventures to Support Day-to-Day Operations EMERYVILLE, Calif., Aug. 9, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS) ("Amyris" or the "Company"), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it is moving forward with an operational and financial restructuring to further advance its ongoing strategic transformation and position the Company for long-term success.
EMERYVILLE, Calif., June 26, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer. The Company also announced a global reduction in force as an important step towards its previously announce
3 - AMYRIS, INC. (0001365916) (Issuer)
3 - AMYRIS, INC. (0001365916) (Issuer)
3 - AMYRIS, INC. (0001365916) (Issuer)
Jefferies downgraded Amyris from Buy to Hold and set a new price target of $0.65 from $3.10 previously
TD Cowen downgraded Amyris from Outperform to Market Perform and set a new price target of $1.25 from $4.00 previously
Canaccord Genuity initiated coverage of Amyris with a rating of Buy and set a new price target of $1.50